Literature DB >> 11444763

Do some antidepressants work faster than others?

A A Nierenberg1.   

Abstract

The clinical utility of antidepressant drugs is impaired by the delay in onset of their therapeutic action. It is becoming increasingly clear that differences exist between antidepressants with respect to this property, both within and between pharmacologic classes. Post hoc analyses of comparisons between selective serotonin reuptake inhibitors and dual-action antidepressants such as mirtazapine and venlafaxine indicate that the dual-action drugs may have a faster onset of action. At least in the case of mirtazapine, the earlier onset appears to be via a specific antidepressant effect and not an effect on sleep or other accessory symptoms. Studies that compare mirtazapine and venlafaxine are relatively rare and lack sufficient statistical power to determine a difference in the onset of action. Although these differences have been shown in clinical efficacy studies not specifically designed to detect differences in onset of action, a definitive demonstration of early onset of action awaits the results of appropriately designed and powered clinical studies currently planned or in progress.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11444763

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  13 in total

1.  Chronic social defeat stress model: behavioral features, antidepressant action, and interaction with biological risk factors.

Authors:  E Venzala; A L García-García; N Elizalde; P Delagrange; R M Tordera
Journal:  Psychopharmacology (Berl)       Date:  2012-06-16       Impact factor: 4.530

2.  Implication of 5-HT2 receptor subtypes in the mechanism of action of antidepressants in the four plates test.

Authors:  Bríd Aine Nic Dhonnchadha; Nadège Ripoll; Florence Clénet; Martine Hascoët; Michel Bourin
Journal:  Psychopharmacology (Berl)       Date:  2004-11-18       Impact factor: 4.530

3.  Chronic fluoxetine increases cytosolic phospholipase A(2) activity and arachidonic acid turnover in brain phospholipids of the unanesthetized rat.

Authors:  Ho-Joo Lee; Jagadeesh S Rao; Renee N Ertley; Lisa Chang; Stanley I Rapoport; Richard P Bazinet
Journal:  Psychopharmacology (Berl)       Date:  2006-11-09       Impact factor: 4.530

4.  Resting glutamate levels and rapid glutamate transients in the prefrontal cortex of the Flinders Sensitive Line rat: a genetic rodent model of depression.

Authors:  Kevin N Hascup; Erin R Hascup; Michelle L Stephens; Paul E A Glaser; Takashi Yoshitake; Aleksander A Mathé; Greg A Gerhardt; Jan Kehr
Journal:  Neuropsychopharmacology       Date:  2011-04-27       Impact factor: 7.853

Review 5.  Mirtazapine, and mirtazapine-like compounds as possible pharmacotherapy for substance abuse disorders: evidence from the bench and the bedside.

Authors:  Steven M Graves; Roueen Rafeyan; Jeffrey Watts; T Celeste Napier
Journal:  Pharmacol Ther       Date:  2012-08-29       Impact factor: 12.310

Review 6.  New formulations of existing antidepressants: advantages in the management of depression.

Authors:  Trevor R Norman; James S Olver
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

7.  Time course of clinical response to venlafaxine: relevance of plasma level and chirality.

Authors:  Marianne Gex-Fabry; Androniki E Balant-Gorgia; Luc P Balant; Serge Rudaz; Jean-Luc Veuthey; Gilles Bertschy
Journal:  Eur J Clin Pharmacol       Date:  2003-12-24       Impact factor: 2.953

8.  Chronic desipramine treatment rescues depression-related, social and cognitive deficits in Engrailed-2 knockout mice.

Authors:  J Brielmaier; J M Senerth; J L Silverman; P G Matteson; J H Millonig; E DiCicco-Bloom; J N Crawley
Journal:  Genes Brain Behav       Date:  2014-03       Impact factor: 3.449

9.  Efficacy and safety of add on low-dose mirtazapine in depression.

Authors:  Prithpal S Matreja; Dinesh K Badyal; Randhir S Deswal; Arvind Sharma
Journal:  Indian J Pharmacol       Date:  2012-03       Impact factor: 1.200

10.  Enhancing central noradrenergic function in depression: is there still a place for a new antidepressant?

Authors:  Roger M Pinder
Journal:  Neuropsychiatr Dis Treat       Date:  2005-03       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.